Age Verification
You must be 21 years or older to view this site.
Are you 21 or older?
You must be 21 years or older to view this site.
Are you 21 or older?
Sorry, you must be 21 or older to view this site.
IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is a synthetic, long-acting analog of the naturally occurring human IGF-1 peptide.1 It is modified to have an extended half-life and greater systemic effect compared to standard IGF-1.2
The LR3 modification prevents the peptide from binding strongly to the majority of its plasma binding proteins (IGFBPs).3 This dramatically extends its activity from minutes to 20–30 hours, allowing it to circulate throughout the body for much longer, binding to receptors and stimulating powerful anabolic effects.4
Sustained Anabolic Action: Used to stimulate cell growth, muscle recovery, and fat burning over a prolonged period.5 The long half-life provides sustained anabolic signaling throughout the day.
Muscle Growth and Recovery: It enhances protein synthesis and inhibits protein degradation, leading to the growth of more muscle tissue and significantly faster recovery times post-workout.6
Fat Loss: Aids in dissolving fat deposits and improving metabolism, contributing to overall body recomposition.7
Hyperplasia Potential: Research suggests IGF-1 may stimulate muscle cell hyperplasia (creating new muscle fibers) rather than just hypertrophy (enlarging existing fibers), potentially offering long-term growth capacity.
IGF-1 LR3 is typically administered infrequently due to its extended half-life.8
| Feature | Details |
| Administration | Typically administered via subcutaneous injection (fat layer). |
| Dosage | Ranges from 20 mcg to 100 mcg daily, depending on experience. |
| Timing | Due to hypoglycemia risk, dose upon waking or immediately post-workout. |
| Duration | Cycles typically last between 4 to 8 weeks. |
IGF-1 LR3 is a potent growth factor; its misuse can have serious health effects, mimicking those of excessive growth hormone.
Hypoglycemia Risk: The most common acute side effect is low blood sugar, as IGF-1 is structurally similar to insulin. Users must consume fast-acting carbohydrates around dosing time.9
Excessive Growth: Abuse can lead to potential organ enlargement (acromegaly), nerve impingement (joint pain/carpal tunnel), and potential harm to the heart.10
Cancer Risk: Due to its ability to stimulate cell division, chronic elevation of IGF-1 is linked to a potential increase in the risk of certain cancers.11
1. What makes the LR3 variant long-acting?
The LR3 modification reduces the peptide's affinity for binding proteins (IGFBPs) that usually neutralize IGF-1 rapidly.12 This allows it to remain active for up to 30 hours, enabling once-daily dosing.13
2. Subcutaneous or Intramuscular injection?
Subcutaneous (into the fat layer) is preferred for a systemic anabolic effect across the whole body. Intramuscular injection is more commonly associated with the IGF-1 DES variant for localized growth.
3. Does it require Post Cycle Therapy (PCT)?
No. IGF-1 LR3 is a growth factor peptide. It does not suppress the body's natural production of testosterone, so standard PCT protocols are not required.
4. Why is organ growth a risk?
As a master anabolic hormone, IGF-1 stimulates cell division in nearly all tissue types. While beneficial for muscle, abuse can cause undesirable growth in organs (like the heart) or bone structure (jaw, hands, feet).
